Kanova
Pioneering advanced therapies in immuno-oncology and autoimmune diseases.
Pioneering advanced therapies in immuno-oncology and autoimmune diseases.
Kanova is a biopharmaceutical company founded in 2015 that focuses on developing therapeutic antibodies and innovative combination therapies in immuno-oncology and autoimmune diseases. The company's slogan, "Pioneering advanced therapies in immuno-oncology and autoimmune diseases," reflects its commitment to cutting-edge medical solutions. In its latest funding round, Kanova secured a significant CNY100.00M Series B investment on 25 July 2023. The investment was led by prominent venture capital firms including Northern Light Venture Capital, Tsinghua Venture Capital, CD Capital, Life Garden Venture Capital, Yangzhou Fengsheng Investment, and ShenZhen GTJA Investment Group. With its focus on the biopharma, health and wellness, and pharmaceutical industries, Kanova is positioned for growth and innovation in the rapidly evolving field of medical therapeutics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | CNY100.00M | 6 |
|
25 Jul 2023 |
| Series B | Unknown | 4 |
|
13 Jul 2021 |
| Series A | CNY115.00M | - | 26 Nov 2018 |
No recent news or press coverage available for Kanova.
We care about your data, and we'd love to use cookies make your experience better.
